Results 11 to 20 of about 15,817 (194)

An HBV-Derived Peptide Poly6 as a Novel Candidate for Functional Cure Via IFN-I-Mediated Epigenetic Regulation of cccDNA. [PDF]

J Med Virol
ABSTRACT Covalently closed circular DNA (cccDNA) represents the central obstacle to achieving a functional cure for chronic hepatitis B virus (HBV) infection. Poly6, a peptide encoded within the HBV genome, was investigated for antiviral efficacy in hepatocyte‐derived cell lines, hydrodynamic injection models, and HBV transgenic mice.
Jang J, Kim DH, Kim Z, Kim E, Choi YM, Kim BJ.   +5 more
europepmc   +2 more sources

Chronic Hepatitis B Relapse Rates after Cessation of Tenofovir Alafenamide and Entecavir Therapy

Biomedicines, 2023
Chronic hepatitis B (CHB) relapse occurs after the cessation of nucleos(t)ide analogues (NUC) therapy due to the waning of viral suppression. Few studies have investigated the viral relapse rate and clinical relapse rate after tenofovir alafenamide (TAF)
Chih-Wen Huang, Chen-Ta Yang, Pei-Yuan Su, Yang-Yuan Chen, Siou-Ping Huang, Hsu-Heng Yen   +5 more
doaj   +1 more source

52-week efficacy and safety of telbivudine with conditional tenofovir intensification at week 24 in HBeAg-positive chronic Hepatitis B [PDF]

, 2013
Background and Aims: The Roadmap concept is a therapeutic framework in chronic hepatitis B for the intensification of nucleoside analogue monotherapy based on early virologic response.
Aldo Trylesinski, AS Levey, AS Lok, BJ McMahon, CJ Chen, CL Lai, DJ Tenney, DJ Tenney, DW Cockcroft, EB Keeffe, Eduardo Fassio, Fernando Bessone, H Izzedine, H Mommeja-Marin, H Yang, Henry L. Y. Chan, HL Chan, Hugo Cheinquer, Javier R. Lama, JD Jia, Jorge Daruich, KL Andersson, Liver European Association For The Study Of The, MF Yuen, MF Yuen, Mário G. Pessôa, N Leung, P Marcellin, Piyawat Komolmit, Rashidkhan Pathan, RD Cooper, RG Gish, S Mauss, S Zeuzem, Stefan Zeuzem, Suzane K. Ono, Tawesak Tanwandee, Teerha Piratvisuth, Wattana Sukeepaisarnjaroen, YF Liaw, YF Liaw, Yuhong Dong   +41 more
core   +10 more sources

Comparative role of tenofovir versus entecavir for treating patients with hepatitis B virus-related acute on chronic liver failure

Journal of Family Medicine and Primary Care, 2021
Introduction: The aim of the study was to compare the safety and efficacy of tenofovir versus entecavir for treatment of naive acute on chronic liver failure (ACLF) due to hepatitis B virus (HBV) (ACLF-B).
Sharker M. S. Hossain, Mamun A Mahtab, Dulal C Das, Sheikh M Noor-E-Alam, Ayub A Mamun, Md. Sakirul I Khan, Sheikh M. F. Akbar, Md Zakiur Rahman, Salimur Rahman   +8 more
doaj   +1 more source

A Case of Severe Peripheral Polyneuropathy Occurring after Entecavir Treatment in a Hepatitis B Patient

The Korean Journal of Gastroenterology, 2016
Entecavir (BaracludeⓇ) is an oral antiviral drug used for the treatment of HBV. Entecavir is a reverse transcriptase inhibitor which prevents the HBV from multiplying.
Ji Hyun Song, Si Yeon Kim, Jae Kyoung Shin, So Dam Hong, Kyu Sung Rim, Ha Na Park, Joo Ho Lee, Yun Bin Lee, Seung Hun Oh, Seong Gyu Hwang   +9 more
doaj   +1 more source

An expert consensus for the management of chronic hepatitis B in Asian Americans. [PDF]

, 2018
BACKGROUND: Hepatitis B virus (HBV) infection is common with major clinical consequences. In Asian Americans, the HBsAg carrier rate ranges from 2% to 16% which approximates the rates from their countries of origin.
Abbas, Abbas, Ahn, Beasley, Beasley, Bisceglie, Bogr, Brown, Buti, Centers for Disease Control, Chae, Chan, Chang, Chang, Chang, Chang, Chang, Chao, Chaung, Chen, Chen, Chen, Chen, Chi, Chien, Choe, Chu, Clemente, Della Corte, European Association for the Study of the Liver, Evans, Fang, Fattovich, Fontana, Fung, Gish, Hadziyannis, Halperin, Hann, Heathcote, Hongthanakorn, Hoofnagle, Hu, Huang, Hung, Hyun, Iino, Iloeje, Jeng, Keeffe, Kim, Komatsu, Konstantinou, Kowdley, Kuo, Kwong, Lai, Lai, Lai, Lai, Lampertico, Lau, Lau, Lee, Lee, Liang, Liaw, Liaw, Liaw, Liew, Lin, Lin, Lin, Liu, Liu, Liu, Lok, Lok, Lok, Loomba, MacLachlan, Manegold, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Marcellin, Martin, Martin-Carbonero, Mast, McClune, McMahon, Mitchell, Monte, Murata, Mutimer, Nafa, Nguyen, Nguyen, Nikolopoulos, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Pan, Papatheodoridis, Park, Park, Park, Patterson, Perrillo, Perrillo, Pollack, Prati, Qiu, Reijnders, Sarin, Seto, Seto, Sherman, Shim, Shiraki, Sinatra, Sinn, Soriano, Stevens, Takano, Takayama, Takkenberg, Terrault, Thibault, Thio, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tong, Tse, Wang, Wedemeyer, Wei, Wen, Wiseman, Wursthorn, Xie, Xu, Yi, Yi, Yu, Yu, Yuen, Yuen, Yuen, Yuen, Yuen, Zhang, Zhang, Zhang, Zou   +173 more
core   +2 more sources

Review Article: Renal Safety Profiles of Tenofovir Alafenamide, Tenofovir Disoproxil Fumarate, and Entecavir for the Treatment of Chronic Hepatitis B Infection-General and Special Populations. [PDF]

Aliment Pharmacol Ther
Current first‐line NUCs show comparable renal safety profiles in CHB patients with no or mild kidney dysfunction, with growing evidence that favours TAF. Future prospective studies are needed to validate these findings, and more research should focus on CHB patients with diabetes mellitus who are at risk of CKD.
Mak LY, Hu TH, Yap DYH.
europepmc   +2 more sources

New Perspectives on Treatment of Hepatitis B Before and After Liver Transplantation [PDF]

, 2016
open5noThe hepatitis B virus (HBV) infects more than 260 million people globally, with increasing incidence, especially in developing countries.
Bortoluzzi, Ilaria, Burra, Patrizia, Ferrarese, Alberto, Russo, Francesco Paolo, Zanetto, Alberto   +4 more
core   +1 more source

Treatment with the Immunomodulator AIC649 in Combination with Entecavir Produces Antiviral Efficacy in the Woodchuck Model of Chronic Hepatitis B

Viruses, 2021
As current interventions for chronic hepatitis B (CHB) rarely induce cure, more effective drugs are needed. Short-term treatment of woodchucks with the novel immunomodulator AIC649, a parapoxvirus-based stimulator of toll-like receptor 9 dependent and ...
Kyle E. Korolowicz, Manasa Suresh, Bin Li, Xu Huang, Changsuek Yon, Xuebing Leng, Bhaskar V. Kallakury, Robin D. Tucker, Stephan Menne   +8 more
doaj   +1 more source

Reactivation of hepatitis B virus with immune-escape mutations after ocrelizumab treatment for multiple sclerosis [PDF]

, 2019
Ocrelizumab is an anti-CD20 monoclonal antibody for the treatment of multiple sclerosis (MS) that is closely related to rituximab. We describe a case of hepatitis B virus (HBV) reactivation in an MS patient with resolved HBV infection receiving ...
Altieri, Marta, Annecca, Rosanna, Aragri, Marianna, Ciardi, Maria R, Iannetta, Marco, Mastroianni, Claudio M, Pontecorvo, Simona, Russo, Gianluca, Salpini, Romina, Svicher, Valentina, Vullo, Vincenzo, Zingaropoli, Maria A   +11 more
core   +1 more source